Toni M Rudisill1, Songzhu Zhao2, Marie A Abate3, Jeffrey H Coben4, Motao Zhu5. 1. Department of Epidemiology, West Virginia University, Morgantown, WV, USA. 2. Injury Control Research Center, West Virginia University, Morgantown, WV, USA. 3. Department of Clinical Pharmacy, West Virginia University, Morgantown, WV, USA. 4. Injury Control Research Center, West Virginia University, Morgantown, WV, USA; Department of Emergency Medicine, West Virginia University, Morgantown, WV, USA. 5. Department of Epidemiology, West Virginia University, Morgantown, WV, USA; Injury Control Research Center, West Virginia University, Morgantown, WV, USA. Electronic address: mozhu@hsc.wvu.edu.
Abstract
OBJECTIVE: Driving under the influence of drugs is a global traffic safety and public health concern. This trend analysis examines the changes in general drug usage other than alcohol, broad categories, and typical prescription and illegal drugs among drivers fatally injured in motor vehicle crashes from 1999 to 2010 in the U.S. METHODS: Data from the Fatality Analysis Reporting System were analyzed from 1999 to 2010. Drug prevalence rates and prevalence ratios (PR) were determined comparing rates in 2009-2010 to 1999-2000 using a random effects model. Changes in general drug usage, broad categories, and representative prescription and illegal drugs including, methadone, oxycodone, hydrocodone, barbiturates, benzodiazepines, and cocaine, were explored. RESULTS: Comparing 2009-2010 to 1999-2000, prevalence of drug usage increased 49% (PR=1.49; 95% confidence interval [CI] 1.42, 1.55). The largest increases in broad drug categories were narcotics (PR=2.73; 95% CI 2.41, 3.08), depressants (PR=2.01; 95% CI 1.80, 2.25), and cannabinoids (PR=1.99; 95% CI 1.84, 2.16). The PR were 6.37 (95% CI 5.07, 8.02) for hydrocodone/oxycodone, 4.29 (95% CI 2.88, 6.37) for methadone, and 2.27 (95% CI 2.00, 2.58) for benzodiazepines. Barbiturates declined in rate over the 12-year period (PR=0.53; 95% CI 0.37, 0.75). Cocaine use increased until 2005 then progressively declined, though the rate remained relatively unchanged (PR=0.94; 95% CI 0.84, 1.06). CONCLUSIONS: While more drivers are being tested and found drug-positive, there is evidence that a shift from illegal to prescription drugs may be occurring among fatally injured drivers in the U.S. Driving under the influence of prescription drugs is a growing traffic concern.
OBJECTIVE: Driving under the influence of drugs is a global traffic safety and public health concern. This trend analysis examines the changes in general drug usage other than alcohol, broad categories, and typical prescription and illegal drugs among drivers fatally injured in motor vehicle crashes from 1999 to 2010 in the U.S. METHODS: Data from the Fatality Analysis Reporting System were analyzed from 1999 to 2010. Drug prevalence rates and prevalence ratios (PR) were determined comparing rates in 2009-2010 to 1999-2000 using a random effects model. Changes in general drug usage, broad categories, and representative prescription and illegal drugs including, methadone, oxycodone, hydrocodone, barbiturates, benzodiazepines, and cocaine, were explored. RESULTS: Comparing 2009-2010 to 1999-2000, prevalence of drug usage increased 49% (PR=1.49; 95% confidence interval [CI] 1.42, 1.55). The largest increases in broad drug categories were narcotics (PR=2.73; 95% CI 2.41, 3.08), depressants (PR=2.01; 95% CI 1.80, 2.25), and cannabinoids (PR=1.99; 95% CI 1.84, 2.16). The PR were 6.37 (95% CI 5.07, 8.02) for hydrocodone/oxycodone, 4.29 (95% CI 2.88, 6.37) for methadone, and 2.27 (95% CI 2.00, 2.58) for benzodiazepines. Barbiturates declined in rate over the 12-year period (PR=0.53; 95% CI 0.37, 0.75). Cocaine use increased until 2005 then progressively declined, though the rate remained relatively unchanged (PR=0.94; 95% CI 0.84, 1.06). CONCLUSIONS: While more drivers are being tested and found drug-positive, there is evidence that a shift from illegal to prescription drugs may be occurring among fatally injured drivers in the U.S. Driving under the influence of prescription drugs is a growing traffic concern.
Authors: Ian R H Rockett; Michael D Regier; Nestor D Kapusta; Jeffrey H Coben; Ted R Miller; Randy L Hanzlick; Knox H Todd; Richard W Sattin; Leslie W Kennedy; John Kleinig; Gordon S Smith Journal: Am J Public Health Date: 2012-09-20 Impact factor: 9.308
Authors: Olaf H Drummer; Jim Gerostamoulos; Helen Batziris; Mark Chu; John R M Caplehorn; Michael D Robertson; Philip Swann Journal: Forensic Sci Int Date: 2003-07-08 Impact factor: 2.395
Authors: J Elise Bailey; Phoebe Lindsey Barton; Dennis Lezotte; Steven R Lowenstein; Richard C Dart Journal: Drug Alcohol Depend Date: 2006-02-28 Impact factor: 4.492
Authors: Silvia Ravera; Sylvia A Hummel; Pieter Stolk; Rob E Heerdink; Lolkje T W de Jong-van den Berg; Johan J de Gier Journal: Eur J Clin Pharmacol Date: 2009-07-21 Impact factor: 2.953
Authors: Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield Journal: Neuropharmacology Date: 2018-06-05 Impact factor: 5.250
Authors: Eduardo Gutierrez-Abejón; Francisco Herrera-Gómez; Paloma Criado-Espegel; F Javier Alvarez Journal: BMJ Open Date: 2017-11-22 Impact factor: 2.692
Authors: Toni M Rudisill; Motao Zhu; Danielle Davidov; D Leann Long; Usha Sambamoorthi; Marie Abate; Vincent Delagarza Journal: BMC Res Notes Date: 2016-03-15
Authors: Francisco Herrera-Gómez; Eduardo Gutierrez-Abejón; Paloma Criado-Espegel; F Javier Álvarez Journal: Front Pharmacol Date: 2018-04-26 Impact factor: 5.810